Interim Analysis of Prodige 9, a Randomized Phase III Trial Comparing No Treatment to Bevacizumab Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer

T. Aparicio,J. Bennouna,K. Le Malicot,F. Ghiringhelli,V. Boige,J. Taieb,O. Bouché,E. Francois,J. Phelip, F. Borel,R. Faroux,J. Seitz,S. Jacquot,D. Genet, C. Lepage

Annals of oncology : official journal of the European Society for Medical Oncology（2014）

引用 3|浏览18

暂无评分

摘要

Aim: The FOLFIRI + bevacizumab (bev) regimen is a standard 1st-line chemotherapy (CT) in metastatic colorectal cancer (mCRC). Several trials have evaluated chemotherapy-free intervals (CFI) with the aim of prevening patients (pts) from experiencing toxicities, with conflicting results.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要